Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

Phase 3

Completed

• Conditions: Allergy

• Registration Number: NCT00309036
• Lead Sponsor: Allergopharma GmbH & Co. KG

Brief Summary

The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Study First Submitted: 2006-03-30
• Study First Submitted QC: 2006-03-30
• Study First Posted: 2006-03-31
• Primary Completion: 2006-09
• Study Completion: 2008-05
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-08
• Last Update Posted: 2013-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Positive Skin Prick Test reaction to grass pollen
• Positive RAST result to grass pollen
• Positive Provocation Test result to grass pollen

Exclusion Criteria

• Serious chronic diseases
• Other relevant perennial allergies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Allergopharma GmbH & Co. KG; 🇩🇪 Reinbek, Germany